| Eltrombopag Olamine in Improving Platelet Recovery in Older Patients With Acute Myeloid Leukemia Undergoing Chemotherapy (NCT02071901) | Case Comprehensive Cancer Center | 2014-08-14 |
| Eltrombopag Olamine in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia (NCT01550185) | Roswell Park Cancer Institute | 2012-05-01 |
| Azacitidine, Mitoxantrone Hydrochloride, and Etoposide in Treating Older Patients With Poor-Prognosis Acute Myeloid Leukemia (NCT01260714) | National Cancer Institute (NCI) | 2010-12-01 |
| Entinostat and Sorafenib Tosylate in Treating Patients With Advanced or Metastatic Solid Tumors or Refractory or Relapsed Acute Myeloid Leukemia (NCT01159301) | National Cancer Institute (NCI) | 2010-06-01 |
| Tipifarnib and Bortezomib in Treating Patients With Acute Leukemia or Chronic Myelogenous Leukemia in Blast Phase (NCT00383474) | National Cancer Institute (NCI) | 2006-08-01 |
| Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia (NCT00352365) | National Cancer Institute (NCI) | 2006-06-01 |
| Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative Disorders (NCT00357305) | National Cancer Institute (NCI) | 2006-05-01 |
| Sorafenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia (NCT00131989) | National Cancer Institute (NCI) | 2005-06-01 |
| 17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic Cancer (NCT00103272) | National Cancer Institute (NCI) | 2005-04-01 |
| Tanespimycin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Chronic Myelomonocytic Leukemia, or Myelodysplastic Syndromes (NCT00098423) | National Cancer Institute (NCI) | 2004-11-01 |
| XK469R in Treating Patients With Refractory Hematologic Cancer (NCT00095797) | National Cancer Institute (NCI) | 2004-10-01 |
| Idarubicin and Cytarabine With or Without Bevacizumab in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia (NCT00096148) | National Cancer Institute (NCI) | 2004-10-01 |
| Flavopiridol in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia (NCT00101231) | National Cancer Institute (NCI) | 2004-10-01 |
| Idarubicin, Cytarabine, and Tipifarnib in Treating Patients With Newly Diagnosed Myelodysplastic Syndromes or Acute Myeloid Leukemia (NCT00096122) | National Cancer Institute (NCI) | 2004-09-01 |
| Cilengitide in Treating Patients With Acute Myeloid Leukemia (NCT00089388) | National Cancer Institute (NCI) | 2004-07-01 |
| Tipifarnib in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia (NCT00027872) | National Cancer Institute (NCI) | 2001-10-01 |
| Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid Leukemia (NCT00006363) | National Cancer Institute (NCI) | 2000-11-01 |